Table 2.
Effect of therapies on Fugl-Meyer Upper Extremity scale
| ULC therapy | RFVE therapy | ||||||
|---|---|---|---|---|---|---|---|
| |
|
n |
Before |
After |
n |
Before |
After |
| Overall |
|
113 |
41.1 ± 17.6 |
44.1 ± 17.3* |
263 |
41.7 ± 16.1 |
48.2 ± 15.2*† |
| Motor impairment |
F-M UE score ≤ 20 |
19 |
11.1 ± 6.5 |
14.6 ± 8.5* |
35 |
11.8 ± 5.2 |
19.0 ± 9.0*† |
| 21 ≤ F-M UE score ≤ 40 |
29 |
32.5 ± 5.5 |
36.1 ± 6.8* |
72 |
32.2 ± 5.9 |
41.5 ± 7.6*† |
|
| F-M UE score > 40 |
65 |
53.8 ± 7.1 |
55.9 ± 8.1* |
156 |
52.7 ± 7.3 |
57.8 ± 6.4*† |
|
| Stroke to Rehabilitation Interval | ≤ 3months |
32 |
47.7 ±16.4 |
51.3 ± 15.2* |
68 |
44.9 ± 14.0 |
53.8 ± 11.5*† |
| 3 < months < 12 |
57 |
38.9 ± 17.5 |
41.7 ± 17.2* |
113 |
39.5 ± 17.2 |
46.0 ± 16.0*† |
|
| ≥ 12 months | 24 | 37.7 ± 17.7 | 40.3 ± 18.0* | 82 | 41.8 ± 15.9 | 46.7 ± 15.7* | |
Data are presented as mean ± SD. n number of patients, ULC Upper Limb Conventional, RFVE Reinforced Feedback in Virtual Environment, F-M UE Fugl – Meyer Upper Extremity.
* p ≤ 0.05 within group analysis (Wilcoxon test).
† p ≤ 0.05 between group analysis (Mann–Whitney U test).